S
Sophie Taillibert
Researcher at University of Paris
Publications - 61
Citations - 4606
Sophie Taillibert is an academic researcher from University of Paris. The author has contributed to research in topics: Radiation therapy & Temozolomide. The author has an hindex of 25, co-authored 60 publications receiving 3559 citations. Previous affiliations of Sophie Taillibert include University of Lausanne & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp,Roger Stupp,Roger Stupp,Sophie Taillibert,Sophie Taillibert,Andrew A. Kanner,William L. Read,William L. Read,David M. Steinberg,Benoit Lhermitte,Steven A. Toms,Ahmed Idbaih,Manmeet Ahluwalia,Karen Fink,Francesco Di Meco,Frank S. Lieberman,Jay-Jiguang Zhu,Jay-Jiguang Zhu,Giuseppe Stragliotto,David Tran,Steven Brem,Steven Brem,Andreas F. Hottinger,Eilon D. Kirson,Gitit Lavy-Shahaf,Uri Weinberg,Chae-Yong Kim,Sun Ha Paek,Garth Nicholas,Jordi Burna,H Hirte,Michael Weller,Yoram Palti,Monika E. Hegi,Zvi Ram +34 more
TL;DR: In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance Temozolmide alone, resulted in statistically significant improvement in progression-free survival and overall survival.
Journal ArticleDOI
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp,Eric T. Wong,Andrew A. Kanner,David M. Steinberg,Herbert H. Engelhard,Volkmar Heidecke,Eilon D. Kirson,Sophie Taillibert,Frank Liebermann,Vladimír Dbalý,Zvi Ram,J. Lee Villano,Nikolai G. Rainov,Uri Weinberg,David Schiff,Lara Kunschner,Jeffrey J. Raizer,Jérôme Honnorat,Andrew E. Sloan,Mark G. Malkin,Joseph Landolfi,F. Payer,Maximilian Mehdorn,Robert J. Weil,Susan C. Pannullo,Manfred Westphal,Martin Smrčka,Lawrence S. Chin,Herwig Kostron,Silvia Hofer,Jeffrey N. Bruce,Rees Cosgrove,Nina Paleologous,Yoram Palti,Philip H. Gutin +34 more
TL;DR: No improvement in overall survival was demonstrated, however efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma.
Journal ArticleDOI
Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article.
Laurent Capelle,Denys Fontaine,Emmanuel Mandonnet,Luc Taillandier,Jean Louis Golmard,Luc Bauchet,Johan Pallud,Philippe Peruzzi,Marie Hélène Baron,Michèle Kujas,Jacques Guyotat,Remi Guillevin,Marc Frenay,Sophie Taillibert,Philippe Colin,Valérie Rigau,F. Vandenbos,Catherine Pinelli,Hugues Duffau,French Réseau d'Étude des Gliomes +19 more
TL;DR: This large series with its volumetric assessment refines the prognostic value of previously stressed clinical and radiological parameters and highlights the importance of tumor size and location.
Journal ArticleDOI
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
Alexandre Carpentier,Florence Laigle-Donadey,Sarah Zohar,Laurent Capelle,Anthony Behin,Annick Tibi,Nadine Martin-Duverneuil,Marc Sanson,Lucette Lacomblez,Sophie Taillibert,Louis Puybasset,Rémy Van Effenterre,Jean-Yves Delattre,Antoine F. Carpentier +13 more
TL;DR: In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma, and main side effects were limited to transient worsening of neurological condition and fever.
Journal ArticleDOI
Skull-base metastases.
Florence Laigle-Donadey,Sophie Taillibert,Nadine Martin-Duverneuil,Jerzy Hildebrand,Jean-Yves Delattre +4 more
TL;DR: Clinically, the key feature is progressive ipsilateral involvement of cranial nerves and the overall prognosis is poor, with an overall median survival of about 2.5 years, probably because skull-base metastases appear late in the course of the disease.